Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review
{{output}}
Abemaciclib (ABE) in combination with endocrine therapy represents the mainstay treatment for either endocrine-resistant metastatic or high-risk early-stage HR+/HER2- breast cancer patients. Hence, an adequate knowledge of this agent pharmacodynamic, pharmacok... ...
